Hepatitis C Virus

Slide 1 · Hepatitis C virus

Virology • chronic liver injury • diagnosis • treatment targets

Virology and immune escape

Clinicopathologic progression and hepatic morphology

Diagnostic interpretation and antiviral principles

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain why HCV commonly persists after acute infection.

Interpret HCV RNA, anti-HCV and aminotransferase findings.

Recognize hepatic and extrahepatic manifestations.

Connect viral proteins to direct-acting antiviral targets.

Slide 3 · The central clinicopathologic paradox

Acute infection is usually clinically silent.

Persistent viremia can lead to progressive inflammation and fibrosis.

A clinically well patient may nevertheless have significant liver injury.

Silent acquisition

Persistent HCV RNA

Chronic hepatitis

Fibrosis / cirrhosis

Slide 4 · Where HCV fits among hepatotropic viruses

Hepatitis viruses A–E are major hepatotropic pathogens.

HCV and HBV account for much chronic viral hepatitis.

Overlapping histology makes virologic testing indispensable.

Feature

HCV

Other hepatitis viruses

Genome

Single-stranded RNA

HBV: Partially dsDNA

Chronic infection

Common

HAV: None

Etiology on biopsy

Not specific

Serology / RNA needed

Slide 5 · The population burden is substantial

The textbook estimates approximately 50–60 million infections worldwide.

It describes approximately 2.4 million chronic infections in the United States.

These are textbook figures, not a separately verified current surveillance update.

Worldwide

50–60 million

United States

2.4 million

Transmission

Parenteral

Slide 6 · Transmission is principally blood-borne

Parenteral exposure is the principal route.

Injection drug use and sharps injury provide direct access to blood.

Careful exposure history informs testing but cannot exclude infection.

Infected blood

Parenteral exposure

HCV acquisition

Slide 7 · Injection-associated transmission

Sharing injection equipment allows contaminated blood transfer.

Multiple blood exposures can occur within an injection network.

Transmission risk is linked to contact with infected blood—not to symptoms.

Contaminated implement

Blood exposure

Susceptible host

Slide 8 · Other clinically important exposure settings

Needlestick injury is an occupational exposure.

Sexual and perinatal transmission can occur.

Epidemiologic histories may identify repeated contacts with infected persons.

Healthcare / sharps

Sexual contact

Perinatal exposure

Slide 9 · Blood screening changed the transmission landscape

Donor screening greatly reduced transfusion-related HCV.

The textbook contrasts high infection incidence in the mid-1980s with much lower later figures.

Historic exposure histories remain relevant when assessing longstanding infection.

Prescreening era

Blood donor screening

Marked decline in transfusion transmission

Slide 10 · No identified exposure does not exclude HCV

No identifiable risk factor in about one-third of affected people.

Risk assessment alone is therefore insufficient to rule out infection.

Serologic and molecular testing are needed when clinically indicated.

Slide 11 · HCV is an enveloped positive-sense RNA virus

HCV belongs to the Flaviviridae family.

It contains single-stranded RNA with a single open reading frame.

The genomic RNA encodes a polyprotein processed into functional products.

(+) ssRNA

E1 / E2

Slide 12 · The RNA genome encodes one polyprotein

A single open reading frame is translated into a precursor polyprotein.

Proteolytic processing generates envelope and nonstructural functions.

This arrangement makes viral proteases essential replication components.

E1

E2

P7

NS2

NS3/4A

NS5A

NS5B

Single translated polyprotein → viral proteolytic processing

Slide 13 · E1 and E2 are envelope proteins

E1 and E2 are located at the viral envelope.

Anti-E2 antibodies may neutralize circulating virus.

Variation in E2 epitopes enables immune escape.

(+) ssRNA

E1 / E2

Slide 14 · Nonstructural proteins have distinct tasks

NS3/4A: Viral protease and antagonist of antiviral signaling.

NS5A: Component of the replication complex.

NS5B: Viral RNA-dependent RNA polymerase.

Viral protein

Principal role

Antiviral target

NS3/4A

Protease

Protease inhibitors

NS5A

Replication complex

NS5A inhibitors

NS5B

RNA synthesis

Polymerase inhibitors

Slide 15 · HCV replication occurs without DNA integration

The viral RNA is translated and replicated in the infected hepatocyte.

Replication uses a negative-strand RNA intermediate.

HCV has no integrated viral DNA intermediate in its replication cycle.

(+) RNA

(−) RNA template

New (+) RNA

Assembly

Slide 16 · The HCV life cycle has separable targets

Entry is followed by endocytosis and uncoating.

RNA translation and polyprotein cleavage supply replication proteins.

Viral RNA replication precedes assembly and release.

Entry

Uncoating

Translation

RNA replication

Assembly

Original mechanism schematic; Drug targets are proteins acting during these stages

Slide 17 · Entry begins at the hepatocyte surface

Envelope-associated virus binds host cell receptors.

Endocytosis internalizes the particle.

Uncoating releases positive-sense RNA for translation.

Attachment

Endocytosis

Fusion / uncoating

RNA release

Slide 18 · Translation creates the viral protein toolkit

Positive-sense viral RNA functions as a translation template.

A precursor polyprotein is processed by proteases.

Mature viral products can support replication and virion production.

E1

E2

P7

NS2

NS3/4A

NS5A

NS5B

Single translated polyprotein → viral proteolytic processing

Slide 19 · RNA synthesis requires a negative-strand template

NS5B synthesizes complementary negative-strand RNA.

The negative strand templates new positive-strand genomes.

RNA-dependent polymerase function is an effective drug target.

Parental (+) RNA

NS5B polymerase

(−) RNA intermediate

Progeny (+) RNA

Slide 20 · The replication complex coordinates RNA production

NS5A participates in the replication complex.

RNA synthesis is associated with intracellular membrane structures.

Interrupting NS5A impairs successful viral replication.

Viral RNA

NS5A complex

RNA amplification

Genomic RNA

Slide 21 · Assembly closes the replicative cycle

New RNA genomes are packaged into particles.

Envelope acquisition and maturation precede release.

Released HCV particles enable continuing infection of other cells.

New (+) RNA

Viral assembly

Budding / release

Further infection

Slide 22 · The polymerase generates substantial diversity

HCV RNA polymerase has low copying fidelity.

Replication continuously generates genetic variants.

Genetic diversity gives the virus opportunities to evade host pressure.

Replication errors

Sequence variants

Immune selection

Persistence

Slide 23 · Genotypes and quasispecies are not identical

Seven genotypes with multiple subtypes.

Within an infected individual, related variants form quasispecies.

Evolution within the host is relevant to persistent infection.

Level

Definition

Clinical relevance

Genotype

Major viral lineage

Population diversity

Subtype

Subdivision of genotype

Further classification

Quasispecies

Within-host variant swarm

Immune escape potential

Slide 24 · Variation of E2 supports antibody escape

Neutralizing antibodies may target the E2 envelope protein.

Emerging variants can have altered E2 epitopes.

Antibody recognition may fail to eliminate the evolving viral population.

Anti-E2 response

E2 epitope variation

Escape variants

Continued viremia

Slide 25 · NS3/4A also undermines host antiviral defense

NS3/4A protease impairs interferon-mediated cellular responses.

This acts alongside adaptive antibody escape.

Multiple avoidance mechanisms make spontaneous clearance difficult.

Innate signaling inhibited

Adaptive recognition evaded

HCV can persist

Slide 26 · Persistence is an interaction, not one mutation

Ongoing replication supplies new variants.

Host immune pressure selects surviving viral populations.

Interferon antagonism further weakens control.

Persistent infection sustains hepatic immune injury.

Rapid RNA variation

Immune evasion

Persistent replication

Chronic injury

Slide 27 · The incubation period is variable

A 4–26 week incubation interval.

The cited mean incubation is approximately 9 weeks.

The absence of symptoms in the incubation phase does not imply absence of infection.

Exposure

0

RNA measurable

1–3 wk

Antibody emergence

3–6 wk

Clinical recognition

Variable

Qualitative event sequence (not a measured biomarker curve)

Slide 28 · HCV RNA is an early marker of infection

HCV RNA may be detected 1–3 weeks after infection.

RNA detection identifies ongoing viral replication.

It can become positive before antibodies have developed.

Exposure

Beginning

RNA

1–3 wk

Anti-HCV

3–6 wk

Chronicity

Persistent RNA

Qualitative event sequence (not a measured biomarker curve)

Slide 29 · Anti-HCV antibodies arise after a window period

Emergence 3–6 weeks after infection.

Antibody testing may therefore be negative early after exposure.

A negative antibody result cannot alone exclude very recent HCV.

Early exposure

RNA may appear

Serologic window

Anti-HCV negative

Later

Anti-HCV emerges

Qualitative event sequence (not a measured biomarker curve)

Slide 30 · Aminotransferases may increase with early viremia

A rise in aminotransferases may accompany detectable HCV RNA.

Enzyme elevation reflects hepatocyte injury, not direct viral identity.

The biochemical pattern must be interpreted with virologic testing.

HCV replication

Hepatic injury

ALT / AST rise

Confirm with HCV RNA

Slide 31 · Interpreting the two major HCV laboratory markers

Anti-HCV indicates an immune response to HCV exposure.

HCV RNA indicates detectable circulating viral nucleic acid.

The two tests answer different questions and may disagree.

Marker

Interpretation

Anti-HCV antibody

Immune response to exposure

HCV RNA

Viremia at sampling

Slide 32 · RNA positive with negative anti-HCV

Consider very early infection before seroconversion.

The antibody result may also be negative with immunosuppression.

An RNA result directly identifies current viremia.

Anti-HCV

HCV RNA

Interpretation

Negative

Positive

Early / impaired antibody response

Negative

Negative

No evidence in sample; Window still possible

Slide 33 · Anti-HCV and RNA both positive

Antibodies document exposure and an immune response.

Detected RNA supports ongoing HCV infection.

Chronicity requires appropriate longitudinal context, not one isolated antibody result.

Anti-HCV (+)

HCV RNA (+)

Current infection

Assess chronicity

Slide 34 · Anti-HCV positive but RNA undetectable

This can occur after spontaneous clearance or successful treatment.

Antibody positivity does not establish current replication.

The antibody may remain detectable, or may wane over time.

Finding

Implication

Anti-HCV positive

Prior immune exposure

HCV RNA undetectable

No circulating RNA detected

Clinical history

Differentiate cure and past spontaneous clearance

Slide 35 · Serology alone cannot reliably date infection

The timing of exposure may be unknown.

Anti-HCV can persist after virus elimination.

RNA persistence over time establishes continuing infection.

Slide 36 · Acute hepatitis C is usually asymptomatic

Approximately 85% of acute infections are asymptomatic.

Severe acute hepatitis is unusual.

Mild disease at presentation does not predict a harmless long-term course.

Acute clinical course

~85% asymptomatic

Severe acute hepatitis

Rare

Long-term risk

Persistence

Slide 37 · Chronic infection is the characteristic outcome

Progression to chronic infection in 80–90% of cases.

Persistent RNA after several months indicates chronic infection.

Chronicity is biologically compatible with few or no symptoms.

Chronic infection

80–90%

Key marker

Persistent HCV RNA

Clinical phenotype

Often silent

Slide 38 · Aminotransferases fluctuate during chronic HCV

ALT and AST may rise intermittently rather than remain continuously high.

Periods of normal aminotransferases do not exclude ongoing liver injury.

HCV RNA and the broader liver assessment are therefore important.

Persistent virus

Variable inflammation

Fluctuating enzymes

Possible fibrosis

Slide 39 · Normal enzymes are not proof of a healthy liver

HCV-associated damage can progress despite normal transaminases.

Biochemical activity and cumulative fibrosis are different dimensions.

Assessment of chronic infection should not rely on ALT alone.

Measurement

What it primarily reflects

ALT / AST

Current hepatocyte injury

HCV RNA

Detectable viremia

Fibrosis assessment

Accumulated architectural damage

Slide 40 · Cirrhosis can develop after decades

Cirrhosis in roughly one-fifth of chronic infections over 20–30 years.

Fibrosis accumulates through sustained inflammation and wound healing.

Progression is heterogeneous among patients.

Chronic necroinflammation

Portal fibrosis

Bridging fibrosis

Cirrhosis

Slide 41 · Progression depends on host and exposure factors

The textbook associates older age and male sex with progression.

Alcohol use and immunosuppressive therapy are important modifiers.

HBV/HIV coinfection and insulin resistance-associated disease also matter.

Host features

Coexisting infections

Alcohol / metabolic disease

Slide 42 · Metabolic disease can compound HCV injury

Obesity, type 2 diabetes and metabolic syndrome are linked to progression.

Steatosis may coexist with viral inflammatory injury.

Risk interpretation should consider viral and metabolic insults together.

HCV-associated hepatitis

Insulin resistance

Combined liver injury

Fibrosis progression

Slide 43 · Coinfections modify chronic hepatitis

HBV and HIV coinfection are linked to more severe liver disease.

Untreated HIV exacerbates HCV-related liver injury.

Interpret chronic hepatitis within the patient’s complete infectious context.

Context

Pathology implication

HCV alone

Chronic inflammatory injury

HBV with HCV

Additional hepatotropic infection

HIV with HCV

Potential acceleration of liver disease

Slide 44 · A chronic hepatitis pattern has three components

Portal chronic inflammatory infiltrates are characteristic.

Interface activity reflects injury at the limiting plate.

Fibrosis evolves from portal expansion to bridging and cirrhosis.

Portal inflammation

Interface activity

Fibrosis

Architectural remodeling

Slide 45 · Portal inflammation is a central lesion

Lymphocytes, sometimes with plasma cells, accumulate in portal tracts.

The portal compartment becomes expanded by inflammatory cells.

Portal inflammation is common but is not uniquely diagnostic of HCV.

Portal tract

Parenchyma

Schematic — not a histologic specimen

Slide 46 · Interface activity injures periportal hepatocytes

Inflammatory cells cross the portal-parenchymal boundary.

Periportal hepatocytes undergo inflammatory injury.

Interface hepatitis reflects active damage, not simply the presence of lymphocytes.

Portal tract

Parenchyma

Schematic — not a histologic specimen

Slide 47 · Lobular inflammation accompanies portal injury

Inflammation may involve the lobular parenchyma.

Injured hepatocytes may undergo apoptosis or necrosis.

Macrophages remove cellular debris after hepatocyte death.

Portal tract

Parenchyma

Schematic — not a histologic specimen

Slide 48 · HCV can produce prominent portal lymphoid follicles

Lymphoid aggregates or follicles are characteristic supportive features.

They occur within portal tracts on chronic hepatitis specimens.

These findings favor HCV in context but are not specific enough to establish etiology.

Portal tract

Parenchyma

Schematic — not a histologic specimen

Slide 49 · Steatosis is a frequent accompanying feature

Hepatocellular fat accumulation is common with chronic HCV.

Particularly marked steatosis with genotype 3.

Steatosis does not by itself discriminate viral from metabolic liver disease.

Portal tract

Parenchyma

Schematic — not a histologic specimen

Slide 50 · Focal bile duct injury may create a diagnostic pitfall

Chronic HCV may injure small portal bile ducts.

The finding can resemble a biliary disorder.

Its usually focal distribution and the broader inflammatory pattern aid interpretation.

Portal tract

Parenchyma

Schematic — not a histologic specimen

Slide 51 · Acute and chronic patterns are histologically different

Acute hepatitis usually has lobular and portal inflammatory injury.

Chronic hepatitis has sustained portal inflammation with fibrosis.

Morphologic overlap with nonviral diseases necessitates clinical correlation.

Feature

Acute viral hepatitis

Chronic hepatitis

Inflammation

Portal and lobular

Portal dominant ± lobular

Hepatocyte injury

Apoptosis / necrosis

Interface activity

Fibrosis

Not defining

Major chronic feature

Slide 52 · Fibrosis begins in the portal compartment

Persistent injury stimulates fibrogenesis.

Portal and periportal fibrosis precede large bridging scars.

Fibrosis stage measures accumulated matrix deposition.

Portal tract

Parenchyma

Schematic — not a histologic specimen

Slide 53 · Bridging fibrosis links vascular compartments

Fibrous septa may connect portal tracts.

Bridges distort hepatic architecture as disease advances.

Bridging fibrosis should not be confused with bridging necrosis of severe acute injury.

Portal tract

Parenchyma

Schematic — not a histologic specimen

Slide 54 · Cirrhosis is the end-stage architectural pattern

Fibrous septa surround regenerative hepatocyte nodules.

Normal lobular architecture is remodeled.

Cirrhosis creates clinical complications and increases the risk of hepatocellular carcinoma.

Portal tract

Parenchyma

Schematic — not a histologic specimen

Slide 55 · Histologic grade and stage answer different questions

Grade describes the activity of inflammatory hepatocellular injury.

Stage describes the severity of fibrosis.

A patient can have modest current activity but advanced accumulated scarring.

Dimension

Histologic question

Grade

How active is hepatocyte injury?

Stage

How much fibrosis has accumulated?

Viral markers

Is HCV presently detectable?

Slide 56 · Biopsy is not an etiologic molecular test

HCV-associated lymphoid follicles, steatosis and duct injury are clues.

Chronic hepatitis has overlapping patterns across multiple causes.

Specific diagnosis requires anti-HCV and HCV RNA testing in context.

Biopsy pattern

Differential diagnosis

Viral testing

Etiologic attribution

Slide 57 · Chronic hepatitis may remain clinically subtle

Fatigue is a common symptom when chronic hepatitis is symptomatic.

Malaise, decreased appetite and episodic mild jaundice can occur.

Laboratory evidence may precede any subjective illness.

Slide 58 · Immune complexes contribute to extrahepatic disease

Persistent antigen exposure can support circulating immune complexes.

The textbook associates chronic HCV with vasculitis, glomerulonephritis and cryoglobulinemia.

Hepatic and systemic manifestations may coexist.

Persistent antigenemia

Immune complexes

Vascular / renal deposition

Extrahepatic injury

Slide 59 · Cryoglobulinemia is a classic HCV association

Immune complex disease may manifest as cryoglobulinemia.

Systemic involvement can occur despite mild hepatic symptoms.

Recognition of extrahepatic manifestations should prompt appropriate virologic evaluation.

Chronic infection

Circulating immune complexes

Cryoglobulinemic manifestations

Slide 60 · Glomerulonephritis and vasculitis are possible

Immune complexes may involve glomerular and vascular structures.

The mechanism differs from direct hepatocyte injury.

The clinical evaluation must look beyond the liver in selected patients.

HCV persistence

Immune complex formation

Renal / vascular injury

Slide 61 · Cirrhosis links chronic HCV to liver cancer

Individuals with HCV-related cirrhosis have increased HCC risk.

The textbook attributes a substantial fraction of U.S. Liver cancers to HCV.

HCC risk is an important long-term consideration even when symptoms are limited.

Persistent HCV

Chronic hepatitis

Cirrhosis

HCC risk

Slide 62 · A “healthy carrier” state is not recognized for HCV

In HBV, selected asymptomatic low-replication states are described.

The textbook does not recognize a comparable healthy-carrier category for HCV.

RNA-positive patients may still develop injury despite normal enzymes.

HBV context

HCV context

Defined low-replication carrier descriptions

No equivalent healthy-carrier state

HBV serologic categories

RNA detection for current HCV

Slide 63 · HCV and HBV leave different diagnostic clues

HBV may produce ground-glass hepatocytes with viral antigen.

HCV often has portal lymphoid follicles and steatosis.

Neither morphological comparison replaces serologic or molecular confirmation.

Feature

Chronic HBV

Chronic HCV

Ground-glass hepatocytes

Characteristic HBV pattern

Not a defining feature

Portal lymphoid follicles

May occur

Characteristic association

Steatosis

Variable

Common; Genotype 3 notable

Slide 64 · The differential of chronic hepatitis is broad

Autoimmune hepatitis can resemble chronic viral hepatitis.

Drug- or toxin-induced injury may cause overlapping inflammation.

Wilson disease and other liver diseases may show similar hepatitic patterns.

Possible etiology

Why morphology may overlap

HCV

Chronic portal and interface injury

Autoimmune hepatitis

Lymphoplasmacytic inflammation

Drug / toxin

Hepatitic injury patterns

Wilson disease

Chronic hepatitis-like injury

Slide 65 · A coherent testing strategy separates exposure and viremia

Anti-HCV is used for screening in the source text.

Detectable HCV RNA establishes current viral nucleic acid in blood.

Results must be matched to exposure timing and immune status.

Anti-HCV screening

Reactive antibody

Nonreactive antibody

Assess HCV RNA to identify viremia

If early exposure / immunosuppression: Consider RNA

Slide 66 · Early infection and immunosuppression are screening pitfalls

Early infection may precede measurable anti-HCV.

Immunosuppression can blunt an antibody response.

When suspicion remains, HCV RNA offers direct virologic assessment.

High clinical suspicion

Anti-HCV negative

Consider RNA testing

Slide 67 · Direct-acting therapy exploits specific viral functions

Three principal antiviral target classes.

NS3/4A protease and NS5A replication functions are drug targets.

NS5B polymerase inhibitors block viral RNA synthesis.

Target

Functional consequence of inhibition

NS3/4A

Impaired protein processing

NS5A

Disrupted replication complex

NS5B

Inhibited viral RNA synthesis

Slide 68 · Combination therapy counters antiviral resistance

Distinct drug targets reduce the chance that one escape variant dominates.

Combination regimens rather than monotherapy.

Targeting multiple essential stages supports durable viral suppression.

Protease inhibitor

NS5A inhibitor

Polymerase inhibitor

Concurrent blockade of HCV replication

Slide 69 · HCV can be cured because it does not integrate

HCV replicates as RNA and does not integrate into the host genome.

Prolonged inhibition can eliminate detectable replicating virus.

This biological property distinguishes HCV treatment from HIV suppression.

RNA-only replication

Potent combination therapy

HCV RNA undetectable

Sustained response

Slide 70 · Viral response is evaluated using HCV RNA

Successful therapy is assessed through absence of detectable viral RNA.

Anti-HCV antibody may remain positive after virologic cure.

The textbook associates sustained viral response with a very high probability of cure.

After treatment

What it means

HCV RNA undetectable

Virologic response

Anti-HCV still positive

Prior exposure; Not treatment failure

Advanced fibrosis present

Separate ongoing liver risk assessment

Slide 71 · Eliminating HCV does not erase established cirrhosis

Virus eradication interrupts the replicative driver of injury.

Existing advanced fibrosis may remain clinically relevant.

Long-term care still depends on structural liver damage and other risk factors.

HCV treatment

Viremia cleared

Residual cirrhosis possible

Continued liver assessment

Slide 72 · Teaching case: Antibodies negative after exposure

Hypothetical: A patient presents after a recent blood exposure.

Anti-HCV is negative, but ALT is elevated.

Question: Which virologic test best assesses early current infection?

Interpretation: HCV RNA testing can detect infection before seroconversion.

Slide 73 · Teaching case: Normal ALT but HCV RNA detected

Hypothetical: An asymptomatic person has normal aminotransferases.

Both anti-HCV and HCV RNA are positive.

Question: Does normal ALT establish absence of liver disease?

Interpretation: No. Ongoing viremia and accumulated fibrosis require separate assessment.

Slide 74 · Teaching case: Portal lymphoid aggregates

Hypothetical: Chronic hepatitis biopsy shows lymphoid follicles and steatosis.

No viral serology is supplied.

Question: Is the histology alone sufficient to diagnose HCV?

Interpretation: No. These clues are supportive, not pathognomonic; Confirm with virologic testing.

Slide 75 · Teaching case: Antibody persists after treatment

Hypothetical: HCV RNA is undetectable after successful therapy.

Anti-HCV remains positive.

Question: Does persistent antibody establish ongoing infection?

Interpretation: No. Detectable RNA, not persistent antibody, indicates current viremia.

Slide 76 · One integrated model of HCV pathobiology

An error-prone RNA virus evades immune elimination.

Persistent replication promotes chronic necroinflammatory injury.

Portal fibrosis may progress to cirrhosis and HCC.

Direct-acting therapy interrupts essential replication functions.

RNA diversity

Immune escape

Chronic hepatitis

Fibrosis / HCC risk

Slide 77 · Five distinctions to retain

Antibody exposure ≠ RNA-confirmed current infection.

Normal ALT ≠ absence of fibrosis.

Portal lymphoid follicles suggest HCV but are not diagnostic.

Histologic grade ≠ fibrosis stage.

HCV cure ≠ immediate elimination of established cirrhosis.

Slide 78 · Primary sources and scope

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th edition (2026).

Chapter 18, “Hepatitis C Virus,” pp. 758–760.

Supporting parent section: “Viral Hepatitis,” pp. 755–756.

Morphology and associated syndromes: pp. 760–762.